Aldeyra Therapeutics Inc (NASDAQ:ALDX) was up 5.6% during mid-day trading on Tuesday . The company traded as high as $7.23 and last traded at $6.21, with a volume of 467,354 shares trading hands. The stock had previously closed at $5.88.

A number of equities research analysts have recently issued reports on ALDX shares. Stifel Nicolaus started coverage on shares of Aldeyra Therapeutics in a research report on Friday, July 1st. They set a “buy” rating and a $16.00 price objective for the company. Cowen and Company restated a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $13.13.

The stock’s market cap is $37.47 million. The firm’s 50-day moving average price is $5.85 and its 200-day moving average price is $5.24.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.01. On average, equities analysts expect that Aldeyra Therapeutics Inc will post ($1.84) earnings per share for the current year.

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc acquired 700,000 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were purchased at an average price of $5.00 per share, for a total transaction of $3,500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.